The Lion's Den · Male Hormone Health
The lion's field guide to hematocrit and hemoglobin on testosterone.
Almost every man on testosterone will watch this number climb. It is manageable. The trick is respecting it without fearing it.
Rates: Liu et al., Blood Adv 2025 (doi:10.1182/bloodadvances.2024015410). Relative risk: Ponce et al., J Clin Endocrinol Metab 2018 (doi:10.1210/jc.2018-00404).
If your last labs came back with a hematocrit creeping toward the red line, read this before you panic and before you do anything drastic.
You are not broken, and you are not the exception. Raising red blood cells is one of the most reliable things testosterone does to a man's body. It is not a sign the therapy is failing. In many ways it is a sign the therapy is working. The question is never "is my blood thickening," because on testosterone it almost always is to some degree. The real questions are how high, how fast, why, and what is the honest smartest way to bring it back into a safe lane without wrecking everything the therapy gave you.
This guide walks the whole thing end to end. What the number actually means. Why testosterone drives it. Whether "thick blood" is truly dangerous (the honest answer is more nuanced than either the fear-mongers or the reassurers will tell you). The exact numbers to watch. Every lever you can pull to fix it, with the real pros and cons of each, including the one everyone reaches for first that can quietly make things worse. And a clear short-term and long-term plan. No hype. Just what the science says and what a lion needs to know to hold the line.
Read this first
This is education, not medical advice, and it does not replace your own clinician or your own bloodwork. Compounds and doses named here are examples for discussion, not a prescription. Everything is for research and educational purposes, adults 21 and over. Your labs, your risk factors, and your provider decide what you actually do.
90-second self-check
Answer honestly. This is a reflection tool, not a diagnosis, and it does not replace a real blood test. It just tells you how loudly your situation is asking for a conversation with your provider.
Tap everything that is true for you.
Do you know your most recent hematocrit (HCT)?
How do you take your testosterone?
Which of these describe you? (tap all that apply)
Any of these symptoms lately? (tap all that apply)
This reflection is education only, not a diagnosis. Numbers here are simplified from the thresholds discussed below. A single blood draw taken well-hydrated and rested is what actually tells the story, and your provider interprets it.
The basics, done properly
Spin a tube of your blood in a centrifuge and it separates into layers, exactly like the tube in the hero above. The heavy red cells pack at the bottom. A hair-thin pale layer of white cells and platelets (the "buffy coat") sits on top of them. Straw-colored plasma floats above. Hematocrit (HCT) is simply the percentage of that tube taken up by the packed red cells. A typical man sits somewhere around 40 to 50%.
Hemoglobin (Hgb) is the iron-rich protein inside those red cells that actually carries oxygen. Hematocrit and hemoglobin rise and fall together, so on testosterone people usually watch hematocrit as the headline number and hemoglobin as its shadow. When either climbs above the normal ceiling, doctors call it erythrocytosis (more red cells than expected). Testosterone-driven erythrocytosis is generally flagged at roughly hemoglobin above 18.5 g/dL or hematocrit above 52%, though the exact cutoff varies by guideline (Ohlander, Varghese & Pastuszak, Sex Med Rev 2018).
This distinction matters and it is where a lot of men scare themselves needlessly. Polycythemia vera is a bone-marrow cancer driven by a genetic mutation (JAK2), where the marrow makes red cells on its own with the "off switch" (erythropoietin) suppressed. What testosterone causes is a secondary erythrocytosis: an outside signal is politely asking your marrow to make more cells, and the marrow obliges. Erythropoietin is normal or high, JAK2 is negative. As one physician who treats this daily put it in a hormone-optimization talk, you can "look at the polycythemia risk, but it's not true disease of polycythemia" (Dr. Siobhan Newman, Peptide Therapy 2025). Same number on the lab sheet, very different beast underneath.
The honest half-truth you'll hear
You will hear reassuring voices say "you're not thickening your blood, you're just raising your oxygen-carrying capacity, it's not a clotting factor." There is real truth in that: hematocrit is not fibrinogen, and more red cells means more oxygen delivery, which is part of why men feel great. But it is not the whole truth. Packed red cells genuinely do raise blood viscosity (thickness), and viscosity climbs steeply once hematocrit gets high. So the grown-up position is: do not panic, but do not wave it away either. Respect the number.
How common, and what drives it
Across pooled placebo-controlled trials, testosterone raised hemoglobin by about 0.8 g/dL and hematocrit by roughly 3 percentage points on average (Fernandez-Balsells et al., J Clin Endocrinol Metab 2010). Men on testosterone were about 4 times more likely to push hematocrit past 50% (Calof et al., odds ratio 3.69, J Gerontol A 2005), and in the highest-quality trials the relative risk of frank erythrocytosis was 8-fold (Ponce et al., J Clin Endocrinol Metab 2018). A 2025 systematic review of 45 studies found real-world rates as high as 66.7%, with injectables, higher doses, and older age carrying the most risk (Liu et al., Blood Adv 2025).
The single biggest lever is how you take it. The mechanism is peaks: short-acting injections spike testosterone far above normal for days, and those supraphysiologic peaks are what push the marrow hardest. Steady delivery (gels, pellets) causes far less. The difference is not subtle.
Share of men crossing HCT above 50%, by how testosterone is delivered
Same drug. The delivery method changes the risk several-fold.
Pastuszak et al. cohort, reported in Ohlander, Varghese & Pastuszak, Sex Med Rev 2018 (doi:10.1016/j.sxmr.2017.04.001). Bars scaled to the injectable rate.
A network meta-analysis of 29 trials found the same order for how much hematocrit rises: intramuscular short-acting esters worst (about +4.0 points), gels in the middle (+3.0), long-acting injectable and patches lowest (+1.6 and +1.4) (Nackeeran et al., J Urol 2021). And it is the trough and the peaks, not how long you have been on therapy, that predict it: in a 21-year pellet cohort, higher trough testosterone predicted erythrocytosis with an odds ratio of 15, while duration of treatment did not matter at all (Ip et al., Eur J Endocrinol 2010). This is the whole case for smaller, more frequent dosing, which we come back to in the fix menu.
Under the hood
Understanding the mechanism is not academic. It tells you why the standard reflex fix (bleeding it off) can backfire, and why the smartest fixes work. Testosterone raises red cell mass through three converging routes, mapped out most clearly by the Bhasin research group:
Testosterone gives a transient bump to erythropoietin (EPO), the kidney hormone that tells marrow to build red cells. EPO jumped about 58% in the first month in one trial.
It suppresses hepcidin, the hormone that locks iron away. With hepcidin down, more iron is released to feed red-cell production. This is the key one.
Normally, once hemoglobin rises, EPO shuts off. Testosterone resets that set point higher, so the body keeps defending a higher hemoglobin instead of correcting it.
That third point is why erythrocytosis does not always self-correct on therapy: your body has quietly decided a higher hemoglobin is the new "normal" and stops pulling it back (Bachman et al., J Gerontol A 2014). The hepcidin-suppression route is now well mapped down to the molecular level: testosterone's receptor interferes with the Smad signaling that normally switches on hepcidin, so the liver makes less of it and more iron gets built into red cells (Guo et al., Aging Cell 2013). The effect is dose-dependent and linear, and it hits older men harder than younger men at the same dose (Coviello et al., J Clin Endocrinol Metab 2008).
The one line to remember from this section
Because testosterone drives red cells partly by freeing up iron, giving a man on testosterone extra iron usually pours fuel on the fire, and repeatedly bleeding him can eventually push his body to make even more. Hold that thought for the fix menu.
The question everyone actually wants answered
Here is the honest, evidence-first answer, because you deserve better than either scare tactics or hand-waving.
High hematocrit raises blood viscosity, and viscosity rises sharply (not in a gentle straight line) once you get up into the low-to-mid 50s. Thicker blood moves more sluggishly and platelets stick a little more readily. That is real physics, not speculation (Ohlander et al., Sex Med Rev 2018). In the one setting where high hematocrit is unquestionably dangerous, polycythemia vera, a landmark trial (CYTO-PV) showed that keeping hematocrit below 45% cut major clots and cardiovascular death roughly four-fold versus letting it drift to 45-50%. And in general population studies, a 5-point rise in a man's hematocrit tracked with meaningfully higher odds of a venous clot.
Here is the part the internet skips: no randomized or prospective study has ever directly shown that testosterone-induced erythrocytosis causes clots, strokes, or heart attacks. The alarming numbers above come from polycythemia vera (a cancer) and from general-population correlations, and doctors have extrapolated them to TRT (Ohlander et al., 2018). That extrapolation may be right. It may also be partly wrong, because a marrow being politely asked to make more cells is not the same as a mutated marrow churning them out uncontrollably.
The best safety data we have supports caution without panic. In the large, placebo-controlled TRAVERSE trial of over 5,200 higher-risk men, testosterone did not increase major cardiac events (heart attack, stroke, cardiovascular death) over about three years. But it did show more pulmonary embolism, atrial fibrillation, and acute kidney injury in the testosterone group (Lincoff et al., N Engl J Med 2023). Meanwhile a dedicated meta-analysis of testosterone and venous clots found no statistically significant increase (odds ratio 1.41, not significant; Houghton et al., Thromb Res 2018). So the clot signal is real enough to respect, and weak enough that you should not lose sleep if your number is well-managed.
Where the risk is real
The men who genuinely need to take this seriously are those with a personal or family history of clots (DVT/PE), a clotting disorder (thrombophilia), a prior heart attack or stroke, untreated sleep apnea, or a hematocrit that blows past the mid-50s. In those men the theoretical risk stops being theoretical. Testosterone plus an underlying clotting tendency is a documented bad combination (Glueck et al., Clin Appl Thromb Hemost 2016).
Bottom line on danger: a hematocrit of 51 or 52 in a well-hydrated, non-smoking man with no clotting history is a "watch and manage" situation, not an emergency. A hematocrit in the high 50s, or any elevation on top of the risk factors above, is a "act now with your provider" situation. The rest of this guide is about staying in the first category and never drifting into the second.
The numbers to know
Three major bodies have set thresholds. They differ slightly, but they tell the same story: watch it from 50, act by the mid-50s.
The hematocrit ladder
Where the major guidelines say to pay attention, investigate, and intervene.
Endocrine Society 2018 (Bhasin et al., doi:10.1210/jc.2018-00229): don't start above ~48%; hold above 54%. AUA 2018: investigate above 50%, intervene at 54%. BSSM 2023: keep below 53%, or below 48% with a prior clot.
When it shows up, and when it settles
Erythrocytosis is mostly a first-year event. Erythropoietin peaks around month one, hematocrit climbs over the first three to six months, and it usually plateaus by nine to twelve months as the body settles at its new set point. This is exactly why the heaviest monitoring lands in that first stretch.
Typical hematocrit trajectory after starting testosterone
Illustrative shape based on the trial literature, not a promise for any one man.
Trajectory synthesized from Bachman et al. 2014 and Ohlander et al. 2018. Individual results vary widely by dose, formulation, and starting point.
One honest caveat to the word "plateau": the biggest jump really is in year one (in a cohort of 1,073 men followed up to 20 years, average hematocrit rose from about 39% to 45% in the first year), but the cumulative chance of eventually crossing the line keeps creeping up for years afterward - roughly a 10% chance of erythrocytosis by year one, climbing to about 38% by year ten (Madsen et al., J Clin Endocrinol Metab 2021). In that same cohort the strongest risk factors were older age at starting, higher BMI, smoking, long-acting injections, and lung conditions, and the authors' recommended first move for a man running high was refreshingly simple: quit smoking, switch to a transdermal route, and lose weight if BMI is high. So this is a number you keep watching every year, not one that stops mattering after month twelve.
The good news on the other side: once the testosterone signal is reduced or removed, red cells turn over naturally and hematocrit drifts back down over weeks to about three months (full red-cell lifespan is roughly 120 days). Long-acting formulations linger, so they normalize more slowly than short esters.
Before you treat it, confirm it
A high number on one lab draw is not automatically a red-cell problem. Several things fake or inflate it, and chasing a false alarm with a needle is its own harm. Check these before acting:
The full toolkit, with honest pros and cons
There is no single "right" fix. There is a ladder, and you generally climb it from the gentlest, most cause-focused options toward the more aggressive ones. Below is every real lever, each with what it does, the upside, the honest downside, and what to monitor. Tags show whether each is mainly a short-term rescue, a long-term fix, or both.
Corrects the plasma-volume side of the ratio and catches false alarms.
Monitor: repeat the hematocrit well-hydrated and rested before you act on any single high value.
Less testosterone means less erythropoietic push. This treats the driver, not the symptom.
Monitor: trough testosterone and hematocrit about 6 to 12 weeks after any change; aim for mid-normal testosterone with hematocrit under the ceiling. (Okano et al., J Sex Med 2025.)
Flattening the peaks lowers the erythropoietic stimulus for the same weekly dose. Peaks are the driver, so shave the peaks.
Monitor: compare trough testosterone and hematocrit before and after the change (about 8 to 12 weeks).
Transdermal gels avoid the supraphysiologic peaks entirely and carry the lowest erythrocytosis rates of any common formulation.
Monitor: recheck testosterone (steady-state, any time of day for gel) and hematocrit about 6 to 12 weeks after switching. (Fink et al., Sex Med Rev 2025.)
Removing about 500 mL of blood directly drops red-cell mass, lowering hematocrit by roughly 3 points per unit. It is the fastest way to move the number.
Monitor: ferritin (iron stores) and platelets, not just hematocrit. Space or stop draws as iron falls, and do not reflexively replace the iron. Reserve aggressive phlebotomy for a genuinely high, symptomatic number. (Bond, Verdegaal & Smit, Endocr Connect 2024; Tramontana/Quinton, Endocr Connect 2025.)
Physiologically identical to phlebotomy, done at a blood bank, and the blood gets used.
Monitor: even if the blood bank is doing the draws, have your prescriber track hematocrit and ferritin independently. Don't assume the center is managing your iron. (Van Buren et al., Am J Clin Pathol 2020; Cable et al./STRIDE, Transfusion 2017.)
Both remove a hidden oxygen-starvation signal that drives red cells on top of the testosterone.
Monitor: recheck hematocrit about 2 to 3 months after starting CPAP or quitting. Get screened for apnea if you snore, wake unrefreshed, or run high for no obvious reason.
Removing the driver is the single most effective way to drop hematocrit. Usually a temporary "hold and restart lower," not a permanent stop.
Monitor: hematocrit until normal, then reintroduce at a lower dose or a steadier formulation and re-monitor. (Okano et al., 2025.)
The idea is to blunt clot risk directly rather than lower the number. This is the most debated lever, so tread carefully.
Monitor: this is a shared decision with your provider, based on your total cardiovascular risk, not the hematocrit number alone. (Reviews: Gangat & Tefferi; ECLAP data in polycythemia vera.)
Put it together
The mistake most men make is treating a chronic problem with a repeated emergency fix, that is, building their whole life around bleeding off blood every few weeks while the underlying driver never changes. Separate the two timelines.
If your number is high today
So it stops coming back
The one rule, if you take nothing else
Do not chase the number with the needle alone. Bleeding lowers the reading but leaves the cause untouched and can quietly deepen an iron hole. The durable answer almost always lives in the dose, the delivery, and the co-drivers, not in the phlebotomy chair.
The foundation under everything
Lifestyle will not, on its own, rescue a hematocrit of 56. But it sets the baseline you are managing from, and a few habits genuinely move the needle in the right (or wrong) direction.
The most underrated daily lever. Chronic mild dehydration keeps your reading artificially high and your blood genuinely more sluggish. Steady water intake through the day (not slamming it before a lab draw to game the number, which just misleads your provider) keeps plasma volume where it belongs. Coffee and alcohol both pull the other way; go easy, especially on alcohol.
Heavy endurance training raises red-cell mass over time; it is part of why serious cyclists and runners run higher. Acutely, though, exercise expands plasma volume and can make a reading look lower ("athlete's dilution"). Net effect over months in a heavily-training man is a higher true red-cell mass, so if you are pushing big aerobic volume on testosterone, factor that in. Resistance training is not a meaningful driver. And do not relocate to high altitude with a marginal hematocrit without expecting it to climb.
These two knot together through apnea. Excess weight and poor sleep drive obstructive sleep apnea, apnea drives nighttime oxygen dips, and those dips drive red cells on top of your testosterone. Losing weight and treating apnea attack that whole chain, and losing weight often raises your own natural testosterone too, which can let you run a lower dose. Prioritize real sleep and airway health; this is not soft advice, it is direct hematocrit management.
You do not need to fear red meat, but a man running high who is also loading iron (supplements, iron-fortified "greens" powders, or a stacked multivitamin) is feeding the exact pathway testosterone already revs. Unless a lab shows you are truly iron-deficient, there is no reason to supplement iron on testosterone. Keep alcohol moderate; it dehydrates and stresses the same cardiovascular system you are trying to protect.
Cutting through the noise
The internet is full of "blood-thinning" supplement stacks for TRT. Here is the honest grading. We would rather tell you something is unproven than sell you hope.
Testosterone raises red cells partly by freeing up iron. Adding more iron feeds the fire. The only exception is a documented deficiency, often after repeated phlebotomy, and even then it should be cautious and provider-guided.
Hydration genuinely helps the relative component and overall flow. Omega-3s have modest, general cardiovascular support but are not a proven hematocrit or clot fix in this setting. Fine as foundation, not as a treatment.
These have interesting lab-dish effects on platelets or iron handling, but zero human evidence that they lower hematocrit or prevent clots in testosterone-induced erythrocytosis. Not harmful in food-like amounts, but do not rely on them to manage a real number.
Marketed hard, studied barely. No credible human trials support them for TRT erythrocytosis, and "natural blood thinner" claims can give false confidence while your actual number stays high. Skip the theater; manage the cause.
The honest peptide angle
Let's be straight: no peptide lowers hematocrit. Anyone selling one for that is selling a story. Where the adjunct conversation genuinely helps is dose-sparing, using your body's own machinery so you need less exogenous testosterone, which means less of the peak-driven push on your marrow in the first place.
The takeaway: peptides are a way to need less testosterone, not a way to counteract thick blood after the fact. If a hematocrit problem is chasing you, the peptide conversation belongs in the "reduce the driver" column, and it belongs with your provider.
You can model any of these protocols, log your labs, and track your hematocrit trend over time in the OnePin app's compound and lab tracking. Cross-reference the Testosterone, hCG, and Enclomiphene entries there for dosing detail and interactions.
Turn this into action
Run through these honestly. They surface most of what drives a rising hematocrit.
Do I actually know my last hematocrit, hemoglobin, and ferritin numbers, and when they were drawn?
Was that blood drawn well-hydrated and at my trough, or could it have been inflated?
Am I taking larger, less frequent injections when smaller, more frequent dosing might serve me better?
Do I snore, wake unrefreshed, or has a partner noticed me stop breathing at night?
Am I still using nicotine in any form?
Am I taking iron or a stacked multivitamin I do not actually need?
Have I been reaching for donation or phlebotomy repeatedly without ever changing the underlying dose or delivery?
Do I have any personal or family history of blood clots that changes my risk math?
Bring these to your visit
What hematocrit ceiling are you managing me to, and does my clot history change it?
Could we lower my dose, split it smaller and more frequent, or switch to a gel instead of relying on phlebotomy?
Should I be screened for sleep apnea?
Are you tracking my ferritin, not just my hematocrit, if I am donating or being phlebotomized?
Given my overall cardiovascular risk, is low-dose aspirin worth it for me, or not?
If my number is unusually high or not tracking my dose, should we check EPO and JAK2 to rule out other causes?
These are the labs and values that tell the real story. Know yours.
Elevated hematocrit rarely causes a sudden event, but if any of these appear, do not wait for your next lab:
For stroke, remember FAST: Face drooping, Arm weakness, Speech difficulty, Time to call emergency services. When in doubt, get checked. No number on a lab sheet is worth gambling on.
The BlessUp take
A rising hematocrit is the most predictable companion of testosterone therapy. It is not a verdict, and it is very rarely an emergency in a man who is paying attention. The men who get into trouble are the ones who either ignore it completely or panic and start bleeding themselves every few weeks while the real driver never changes.
The BlessUp way is the middle path. Know your numbers. Draw them honestly, hydrated and at trough. Rule out the fakes. When it climbs, reach first for the causes, the dose, the delivery, the apnea, the nicotine, before you reach for the needle. Use donation as a bridge, not a lifestyle, and never let it quietly dig you into an iron hole. And keep the whole system in view, because the point was never a perfect percentage. The point was a long, strong life.
You are not the exception. You are handling a common thing well. Keep handling it well.
The evidence
Every quantitative claim above traces to one of these. All are indexed in PubMed; links go to the DOI. A handful of secondary figures (the per-unit hematocrit drop, the smoker's-polycythemia magnitude) are noted in-text as estimates from the review literature rather than a single primary trial.
Plus guideline bodies: AUA Testosterone Deficiency Guideline (2018), BSSM Guidelines on Adult Testosterone Deficiency (2023), and physician teaching from the Peptide Therapy 2025 hormone-optimization sessions (Dr. Siobhan Newman; Dr. Khanh Nguyen).